ATTACK
Adoptive engineered T cell Trials to Achieve Cancer Killing
| Coordinatore | THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 8˙260˙833 € |
| EC contributo | 6˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-12-01 - 2017-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | coordinator | 578˙497.20 |
| 2 |
CELLULAR THERAPEUTICS LIMITED
Organization address
address: HAWTHORN LANE 34 HEALD COURT 3 contact info |
UK (WILMSLOW) | participant | 1˙287˙000.00 |
| 3 |
AMSTERDAM BIOTHERAPEUTICS UNIT
Organization address
address: Louwesweg 6 contact info |
NL (Amsterdam) | participant | 1˙091˙000.00 |
| 4 |
THE CHRISTIE NHS FOUNDATION TRUST
Organization address
address: WILMSLOW ROAD 1 contact info |
UK (MANCHESTER) | participant | 666˙000.40 |
| 5 |
MILTENYI BIOTEC GMBH
Organization address
address: FRIEDRICH EBERT STRASSE 68 contact info |
DE (BERGISCH GLADBACH) | participant | 405˙500.00 |
| 6 |
ADAPTIMMUNE LIMITED
Organization address
address: GARSINGTON ROAD 9400 OXFORD BUSINESS PARK contact info |
UK (OXFORD) | participant | 306˙000.00 |
| 7 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 301˙000.40 |
| 8 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 266˙000.40 |
| 9 |
Ospedale San Raffaele
Organization address
address: Via Olgettina 60 contact info |
IT (Milano) | participant | 266˙000.40 |
| 10 |
STICHTING HET NEDERLANDS KANKER INSTITUUT
Organization address
address: PLESMANLAAN 121 contact info |
NL (AMSTERDAM) | participant | 266˙000.40 |
| 11 |
STOCKHOLMS LAENS LANDSTING
Organization address
address: Hantverkargatan 45 contact info |
SE (STOCKHOLM) | participant | 262˙000.40 |
| 12 |
"Royal Free Hospital, Royal Free Hampstead NHS Trust"
Organization address
address: Pond street contact info |
UK (LONDON) | participant | 122˙000.20 |
| 13 |
UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST
Organization address
address: EUSTON ROAD 250 contact info |
UK (LONDON) | participant | 122˙000.20 |
| 14 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 39˙000.00 |
| 15 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 22˙000.00 |
| 16 |
Fondazione Centro San Raffaele
Organization address
address: Via Olgettina 60 contact info |
IT (Milano) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials needed. This proposal builds upon previous EU funded pre-clinical projects and comprises a multidisciplinary and translational research group with wide-ranging relevant expertise. Building on encouraging clinical results targeting NY-ESO-1 in melanoma and the availability of clinical grade vector, the consortium proposes to rapidly initiate two landmark studies in this field: the first to examine the activity of engineered T cells in oesophago-gastric cancer as an example of a hard to treat common epithelial cancer; the second to undertake a randomised phase II study to determine whether an optimised cell production system developed by the partners improves the current clinical response rates in patients with metastatic melanoma treated with NY-ESO-1 targeted T-cells. Success in these trials will enable the consortia and others to carryout larger trials and potentially approval of this type of therapy as a treatment for multiple cancer types. The inclusion of a major industrial partner focused on cell therapy technology and two SMEs focus on the delivery of cell therapy will facilitate future development of this area following these trials; indeed the project also includes plans to further automate and streamline cell processing to facilitate this development. This project would enhance European expertise and competitiveness in an important emerging market. The research will also support the European biotechnology industry which will be important for the exploitation of these therapies and the successful outcome of this project.'